Short answer
Indivior Pharmaceuticals, Inc. (INDV) filed an 8-K current report with the SEC on September 17, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Exhibit 99.1 furnished under Regulation FD, signaling accompanying investor-relevant disclosure.
Indivior Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Exhibit 99.1 furnished under Regulation FD, signaling accompanying investor-relevant disclosure
- Information not treated as filed under Exchange Act Section 18
- Exhibit excluded from automatic incorporation into other Securities Act or Exchange Act filings
Item 8.01 · Other Events
- $8.13-per-share special cash dividend declared, contingent on Indivior’s acquisition of Supernus closing
- Record date October 30, 2026; payment anticipated around November 6, 2026, assuming November 2 closing
- Dividend also applies to $8.13 per share underlying eligible Indivior equity awards upon vesting
- Majority potentially treated as U.S. shareholder return of capital, then capital gain, subject to tax basis
- Supernus shareholders excluded from the dividend on Indivior shares received in the merger
Item EX-99.1 · Exhibit EX-99.1
- $8.13-per-share special dividend declared for Indivior shareholders of record October 30, 2026
- Payment contingent on Supernus merger closing, currently expected around November 2, 2026
- Eligible shareholders expected to receive payment around November 6, 2026 if closing occurs as planned
- No dividend if the merger fails; Supernus shareholders receiving Indivior shares are excluded
- Additional borrowing to fund the dividend could increase leverage at the combined company
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Indivior Pharmaceuticals, Inc. 8-K filings
Get the next INDV 8-K as it lands
Follow INDV for push alerts, or ask the research agent what this filing means.